FDA ENANTIOMER MARKETING EXCLUSIVITY POLICY MAY BE REVISED, AGENCY ANNOUNCES; WYETH/INTERNEURON REDUX EXCLUSIVITY DETERMINATION TO BE MADE BY PTO, FDA SAYS
Executive Summary
FDA is soliciting comments on the appropriate exclusivity period for single-isomer versions of previously marketed racemic products, the agency announced in a Jan. 15 Federal Register notice.
You may also be interested in...
Forest’s Fetzima Will Test Enantiomer Exclusivity Policy Change
The antidepressant levomilnacipran, an enantiomer of Forest’s fibromyalgia drug Savella (milnacipran), could be the first product to take advantage of an FDA Amendments Act provision that allows enantiomers of previously approved drugs to qualify for five years of new chemical entity exclusivity.
Enantiomers, Antibiotics May Benefit As Hatch Pushes Incentives In FDA Bill
Exclusivity and other incentives to encourage antibiotic development are among the details being negotiated by Senate Health, Education, Labor and Pensions Committee members as part of the FDA Revitalization Act
Enantiomers, Antibiotics May Benefit As Hatch Pushes Incentives In FDA Bill
Exclusivity and other incentives to encourage antibiotic development are among the details being negotiated by Senate Health, Education, Labor and Pensions Committee members as part of the FDA Revitalization Act